Exchange Traded Concepts LLC Sells 11,350 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Exchange Traded Concepts LLC lessened its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 60.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,483 shares of the company’s stock after selling 11,350 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $191,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Quest Partners LLC lifted its position in Enliven Therapeutics by 87.3% in the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the last quarter. American Century Companies Inc. lifted its position in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares during the last quarter. EntryPoint Capital LLC bought a new stake in Enliven Therapeutics in the 1st quarter worth approximately $167,000. SG Americas Securities LLC bought a new stake in Enliven Therapeutics in the 3rd quarter worth approximately $256,000. Finally, Rhumbline Advisers increased its stake in Enliven Therapeutics by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after purchasing an additional 11,420 shares during the period. Institutional investors own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Insider Activity

In other news, Director Rahul D. Ballal sold 10,420 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $28.17, for a total transaction of $293,531.40. Following the transaction, the director now directly owns 22,341 shares of the company’s stock, valued at approximately $629,345.97. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Benjamin Hohl sold 5,250 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $26.68, for a total value of $140,070.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Rahul D. Ballal sold 10,420 shares of the company’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $28.17, for a total value of $293,531.40. Following the completion of the sale, the director now directly owns 22,341 shares in the company, valued at approximately $629,345.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 180,409 shares of company stock valued at $4,800,526. Company insiders own 29.20% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $28.87 on Tuesday. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $30.03. The stock has a market capitalization of $1.36 billion, a P/E ratio of -14.96 and a beta of 1.10. The business’s 50 day simple moving average is $24.23 and its two-hundred day simple moving average is $22.77.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.17. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.